Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioInvent International's partner has initiated a phase I clinical study using n-CoDeR, a proprietary antibody development platform.
Subscribe to our email newsletter
Commencement of the study using the platform has triggered a milestone payment for BioInvent, as per its collaboration agreement with partners who finance the development of the new antibody-based drugs.
BioInvent CEO Cristina Glad said that the advancement by one of its partners of an n-CoDeR antibody into the clinic represented an important step forward for the company.
"Progress in our external drug programmes is a key driver for BioInvent’s development," Glad added.
The company’s pipeline of external drug programmes consists of another seven antibodies in pre-clinical development of which additional candidates are expected to enter clinical trials in 2013.
A research-based pharmaceutical company, BioInvent focuses on discovery and development of innovative antibody-based drugs against cancer and its pipeline currently includes three product candidates to treat cancer.
The company’s partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier.